新型ECCO2R技术在前瞻性临床评估中的应用:PRISMALUNG用于轻中度ARDS患者超肺保护性通气
这项法国前瞻性多中心研究评估了PRISMALUNG+膜肺行ECCO2R在轻中度ARDS患者超肺保护性通气中的性能与安全性。2021年4月至2023年12月共纳入58例患者(其中16例联合CRRT),潮气量从6 mL/kg逐步降至4 mL/kg,当PaCO2超过50 mmHg时启动扫气(100%氧气、10 L/min)。治疗24小时后,潮气量从6.0降至4.0 mL/kg,驱动压从12.0降至10.0 cmH2O,通气比从1.7降至1.3,机械功率从18.8降至11.8 J/min,均p<0.0001;PaO2/FiO2无显著变化,呼吸性酸中毒缓解,未报告大出血、颅内出血或溶血事件。
要点
- 58例轻中度ARDS患者行ECCO2R(16例联合CRRT),潮气量从6 mL/kg逐步降至4 mL/kg,PaCO2>50 mmHg时启动扫气(100%氧气、10 L/min)。
- 治疗24小时后潮气量从6.0降至4.0 mL/kg、驱动压从12.0降至10.0 cmH2O、通气比从1.7降至1.3、机械功率从18.8降至11.8 J/min,均p<0.0001。
- PaO2/FiO2随时间无显著变化,呼吸性酸中毒缓解(pH正常化、PaCO2下降),未诱发低氧血症。
- 研究期间未报告大出血事件、颅内出血或溶血。
- 在超低潮气量通气期间出现的高碳酸血症性酸中毒可通过ECCO2R安全缓解。
适用人群与场景
- 轻中度急性呼吸窘迫综合征(ARDS)的机械通气患者,来自法国多中心前瞻性研究。
- 共58例患者接受ECCO2R治疗,其中16例联合连续肾脏替代治疗(CRRT)。
诊断标准与关键阈值
- 潮气量从6 mL/kg逐步降至4 mL/kg进行超肺保护性通气(ULPV)。
- 当PaCO2超过50 mmHg时启动ECCO2R,扫气条件为100%氧气、10 L/min。
处置流程与药物剂量
- 先行超肺保护性通气:潮气量从6 mL/kg逐步降至4 mL/kg。
- PaCO2超过50 mmHg时启动ECCO2R,扫气用100%氧气、10 L/min。
- ECCO2R可单独使用,也可联合CRRT(本研究中16例联合CRRT)。
研究设计与关键结果
- 研究类型:前瞻性多中心临床研究;样本量58例(16例联合CRRT);人群为轻中度ARDS机械通气患者;干预为PRISMALUNG+行ECCO2R联合超肺保护性通气;无对照组。
- 潮气量降低期间、ECCO2R启动前,高碳酸血症和呼吸性酸中毒峰值达PaCO2 53.0 [50.0-55.0] mmHg、pH 7.30 [7.24-7.36]。
- 治疗24小时后,潮气量从6.0 [6.0-6.1]降至4.0 [4.0-4.30] mL/kg(p<0.0001),驱动压从12.0 [10.0-16.0]降至10.0 [8.0-13.0] cmH2O(p<0.0001),通气比从1.7 [1.5-2.1]降至1.3 [1.0-1.6](p<0.0001),机械功率从18.8 [15.0-22.0]降至11.8 [8.8-15.5] J/min(p<0.0001)。
- PaO2/FiO2随时间无显著变化;呼吸性酸中毒缓解,表现为pH正常化和PaCO2下降。
- 安全性监测至出院或第28天:未报告大出血事件、颅内出血或溶血。
证据类型、等级与局限
- 证据类型:前瞻性多中心临床研究(单臂,无对照组)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在轻中度ARDS机械通气患者中,超低潮气量通气(4 mL/kg)所致高碳酸血症性酸中毒可用ECCO2R安全缓解,且不诱发低氧血症。
- ECCO2R联合超肺保护性通气可降低驱动压、通气比和机械功率。
- 作者认为,超低潮气量通气期间发生的高碳酸血症性酸中毒可通过ECCO2R安全缓解。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Extracorporeal carbon dioxide removal (ECCO2R), when used as an adjunct to mechanical ventilation in patients with mild to moderate acute respiratory distress syndrome (ARDS), has been proposed as a strategy to control hypercapnic acidosis during ultra-lung-protective ventilation (ULPV). However, no multicenter study has systematically assessed ventilation improvement markers with a standardized protocol using ECCO₂R devices featuring a peristaltic pump design. This prospective, multicenter study conducted in France addresses these gaps by evaluating the performance and safety of PRISMALUNG+, a novel membrane lung specifically developed for ECCO2R, either as a standalone therapy or combined with continuous renal replacement therapy (CRRT). A specific protocol for ULPV was used to minimize lung stress and mitigate the risk of hypoxemia.
METHODS: Between April 2021 and December 2023, 58 patients were treated with ECCO2R (16 in combination with CRRT). Tidal volume (VT) was reduced stepwise from 6 mL/kg to 4 mL/kg. Once the partial pressure of carbon dioxide (PaCO2) exceeded 50 mmHg, sweep gas (100% oxygen at 10 L/min) was initiated to provide ECCO2R. Outcomes were measured at 8 and 24 h, while safety was monitored until discharge or day 28.
RESULTS: During VT reduction and before ECCO2R initiation, peak hypercapnia and respiratory acidosis reached PaCO2 of 53.0 [50.0-55.0] mmHg and pH of 7.30 [7.24-7.36]. After 24 h of treatment, VT significantly decreased from 6.0 [6.0-6.1] to 4.0 [4.0-4.30] (p < 0.0001), driving pressure (∆P) from 12.0 [10.0-16.0] cmH2O to 10.0 [8.0-13.0] cmH2O (p < 0.0001), ventilatory ratio (VR) from 1.7 [1.5-2.1] to 1.3 [1.0-1.6] (p < 0.0001) and mechanical power from 18.8 [15.0-22.0] J/min to 11.8 [8.8-15.5] J/min (p < 0.0001). PaO2/FiO2 did not significantly change over time and respiratory acidosis resolved with treatment, as evidenced by normalization of pH and a reduction in PaCO2. Importantly, no major bleeding events, intracranial hemorrhages, or hemolysis were reported during the study.
CONCLUSION: This study demonstrates that hypercapnic acidosis occurring during ultra-low VT ventilation (ULPV) can be safely mitigated with ECCO₂R in mechanically ventilated patients with mild to moderate ARDS. Moreover, under ULPV, ∆P, VR and mechanical power were improved without inducing hypoxemia.
TRIAL REGISTRATION: Clinicaltrials.gov: NCT04617093, Registration date: 30 October 2020.
参考来源
- Combes A, Levy B, Tapponnier R, et al. A prospective clinical evaluation of new ECCO2R technology in mild to moderate ARDS patients: assessing ultra-lung-protective ventilation with PRISMALUNG. Crit Care. 2026. PMID: 41495763. doi:10.1186/s13054-025-05827-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。